Core Viewpoint - Iridex Corporation is set to release its financial results for Q2 2025 and provide a business update on August 12, 2025, indicating ongoing developments in the company's operations and financial performance [1]. Company Overview - Iridex Corporation is a leader in the development, manufacturing, and marketing of innovative laser-based medical systems and devices for the ophthalmology market [3]. - The company specializes in products for treating glaucoma and diabetic macular edema (DME), utilizing its proprietary MicroPulse® technology for effective laser treatments [3]. - Iridex's products are distributed in over 100 countries, with sales in the U.S. conducted through a direct sales force and international sales through independent distributors [3]. Upcoming Events - A conference call will be held on August 12, 2025, at 2:00 p.m. PT / 5:00 p.m. ET for investors to discuss the financial results and business updates [2]. - Investors can access the call by dialing +1-888-596-4144 with the passcode 2197032, and a live and recorded webcast will be available on the company's website [2].

Core Insights - Iridex Corporation has announced the successful enrollment of the first patient in the DAME Trial, which aims to evaluate the efficacy, safety, cost-effectiveness, and patient acceptability of adding subthreshold MicroPulse treatments to anti-VEGF therapy for severe diabetic macular edema (DME) [1][2] Company Overview - Iridex Corporation is a leader in developing and marketing innovative laser-based medical systems for ophthalmology, including treatments for glaucoma and retinal diseases [7][8] - The company's proprietary MicroPulse technology minimizes tissue damage while delivering therapeutic benefits, making it a safe and effective treatment option [7] Trial Details - The DAME Trial is an independent, investigator-led study involving at least 20 clinical sites and 264 participants across the UK, focusing on patients with severe DME [2][5] - The trial aims to establish a new treatment pathway by assessing the addition of subthreshold MicroPulse laser therapy after anti-VEGF treatment, specifically when central retinal thickness (CRT) is below 400 μm [2][5] Expected Outcomes - The primary goal of the DAME Trial is to demonstrate equivalence in best-corrected visual acuity outcomes between the two treatment arms over a 24-month period [5] - Secondary outcomes will include quality of life, cost-effectiveness, treatment burden, and patient-reported experiences [5] Significance of the Trial - The DAME Trial could potentially transform the management of DME by reducing the frequency of anti-VEGF injections, thereby lowering associated risks, costs, and patient burden [3][4] - The trial builds on the success of the DIAMONDS study, which previously demonstrated the safety and effectiveness of subthreshold MicroPulse laser treatment for DME [6]

Company Overview - Iridex Corporation is a global leader in developing, manufacturing, and marketing innovative laser-based medical systems, delivery devices, and consumable instrumentation for the ophthalmology market [3] - The company's proprietary MicroPulse® technology offers a differentiated laser treatment that is safe, effective, and proven for targeted sight-threatening eye conditions [3] - Iridex's product line is utilized for treating glaucoma, diabetic macular edema (DME), and other retinal diseases [3] - Products are sold in the U.S. through a direct sales force and internationally via a network of independent distributors in over 100 countries [3] Upcoming Financial Results - The company plans to release its financial results for the first quarter of 2025 and provide a business update after the close of trading on May 13, 2025 [1] - A conference call will be hosted by the management team at 2:00 p.m. PT / 5:00 p.m. ET on the same day [2] - Investors can access the conference call by dialing +1-888-596-4144 and using conference ID: 698002, with a live and recorded webcast available on the company's website [2]

Core Insights - Iridex Corporation has announced preliminary unaudited operational and financial results for Q1 2025, indicating a stabilization of the business and improved financial condition following a strategic investment by Novel Inspiration International Co., Ltd [1][3] Financial Performance - Total revenue for Q1 2025 is expected to be between $11.8 million and $12.0 million, consistent with $11.8 million in the same quarter of 2024 [7] - The company sold approximately 13,900 Cyclo G6 probes in Q1 2025, an increase from 13,300 in the prior year quarter [7] - The sales of Cyclo G6 Laser Systems rose to approximately 24 units in Q1 2025, compared to 22 units in the prior year quarter [7] - Cash and cash equivalents as of March 29, 2025, were reported at $7.2 million [7] Strategic Outlook - The company aims to achieve breakeven or better performance at historical revenue levels despite external factors such as changes in tariff policies [3] - An investor call is scheduled for April 16, 2025, to discuss Iridex and Novel's strategic vision for the company [3] Company Overview - Iridex Corporation specializes in developing, manufacturing, and marketing laser-based medical systems and devices for the ophthalmology market, particularly for treating glaucoma and retinal diseases [4] - The company's proprietary MicroPulse® technology offers a differentiated laser treatment for sight-threatening eye conditions [4] - Iridex products are distributed in over 100 countries, primarily through independent distributors [4]

Core Insights - Iridex Corporation will host a special call on April 16, 2025, to discuss its strategic vision following a recent investment from Novel [1] - The conference call will begin at 2:00 p.m. PT / 5:00 p.m. ET, and investors can participate by dialing 888-596-4144 with conference ID: 9584140 [2] - Iridex is a leader in developing laser-based medical systems for ophthalmology, focusing on treatments for glaucoma and retinal diseases [3] Company Overview - Iridex Corporation specializes in innovative laser-based medical systems, delivery devices, and consumable instrumentation for the ophthalmology market [3] - The company's proprietary MicroPulse® technology offers a differentiated laser treatment for sight-threatening eye conditions [3] - Iridex's products are marketed in over 100 countries, with a direct sales force in the United States and independent distributors internationally [3]